NephroCheck data compared to serum XXXX in various clinical settings.

@entity1552 @entity8 @entity712 @entity5721 @entity13645 @entity810 @entity1011 @entity454
BACKGROUND: @entity810 is frequently observed at the intensive care unit, after surgery, and after toxic drug administration. A rise in serum @entity1011 and a fall in urine output are consequences of much earlier injury to the most sensitive part of tubular cells located at the proximal tubule. The aim of the present study was to investigate the course of two cell-cycle arrest urinary biomarkers compared to serum @entity1011 in four clinical settings: @entity5721 , @entity712 , severe @entity810 , and chemotherapy-induced @entity8 . METHODS: A recently developed bedside test known as NephroCheck measures two urinary parameters: @entity13645 ( @entity13645 ) and @entity1552 ( @entity1552 ). The test is based on a sandwich immunoassay technique. The final test output, labeled AKIRisk, is shown as a numeric result. RESULTS: This report revealed that [ @entity13645 ]        [ @entity1552 ] in urine rise rapidly prior to any change in serum @entity1011 . A unique feature of all four clinical settings is that a rapid decline predicts the recovery of kidney function. Besides, a subclinical @entity8 might be detected by the test. CONCLUSION: This bedside test detects biomarkers of @entity8 . A rapid decline in AKIRisk was associated with the restoration of kidney function, whereas a prolonged high AKIRisk score was associated with @entity454 . However, the dynamics seem to differ, depending on the cause and the extent of injury. Further studies will be needed to clarify the issue.
